by Dr. C.H. Weaver M.D. updated 2/2021

HER2 (human epidermal growth factor 2) is a receptor on the surface of breast cells. When HER2 is "turned on" it causes the cells to grow and reproduce. Normal breast cells have 2 copies of the gene that makes HER2. In contrast to normal breast cells some have more than two HER2 genes and/or produce too much HER2. This results in more HER2 receptors on breast cells - a condition doctors refer to as "over expression" Over expression of HER2 leads to increased breast cell production or cancer.

Doctors can test for HER2 with two different tests.

  • IHC - measures the number of HER2 receptors on a scale of 1-3. 3 + means there are too many.
  • ISH - counts the number of HER2 genes.

HER2 + "positive" breast cancers can be treated with precision cancer medicines that target the HER2 receptor. Approximately 20-25% of breast cancers. These cancers are referred to as HER2-positive.

There are several precision cancer medicines that target HER2 and the use of these medications improves the outcomes of women with both early-stage and advanced HER2-positive breast cancer.

Herceptin (trastuzumab)

Recommended Articles

Image placeholder title

Jakafi Superior to Standard Therapy for Polycythemia Vera

Jakafi superior symptom control, delays phlebotomy, and improves outcomes for individuals with Polycythemia Vera.

Non Small Cell Lung Cancer News Updates NSCLC

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patient

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers

Next Generation anti HER2 Precision Cancer Medicines

  • Tykerb Tykerb in Advanced Breast Cancer
  • Perjeta - targets different part of HER2 than Herceptin
  • Nerlynx - TKI that targets HER2 at multiple levels.
  • Kadcyla (T-DM1)- combines Herceptin with chemotherapy.
  • Enhertu- antibody-drug conjugate FDA approved for advanced disease.
  • Tucatinib - FDA approved and highly effective
  • Margetuximab - in development.
  • Pyrotinib - in development

What are the side effects of HER2 therapies?

Should all HER2 + breast cancers be treated?

  • All invasive and metastatic HER 2 positive breast cancers benefit from HER2 directed therapy. Even very small cancers appear to benefit. A U.S. study evaluated the records of 965 women with small cancers that had not been treated with HER2-targeted therapy or chemotherapy. By the end of five years, 6% of women with HER2-negative breast cancer had a recurrence compared with 23% of women with HER2-positive breast cancer.

What is the role of HER 2 in DCIS?

Compared with invasive breast cancer, DCIS more often expresses HER2, however current research does not support the use of human HER2 - directed therapy in DCIS.

References:

  1. nccn.org/patients/guidelines/breast-invasive/22/
  2. Roses RE, Paulson EC, Sharma A et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2009 18: 1386-1389.
  3. Gonzalez AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Journal of Clinical Oncology[early online publication]. November 2, 2009.
  4. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Journal of Clinical Oncology [early online publication]. November 2, 2009.
  5. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. Journal of Clinical Oncology [early online publication]. November 2, 2009.​
  6. nccn.org/patients/guidelines/stage_iv_breast/30/
  7. NCCN Guidelines Version 3.2013 Ductal Carcinoma in Situ (Accessed on August 07, 2013).
  8. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23:974.